COMMON VARIABLE IMMUNODEFICIENCY AND INCLUSION-BODY MYOSITIS - A DISTINCT MYOPATHY MEDIATED BY NATURAL-KILLER-CELLS

被引:43
作者
DALAKAS, MC
ILLA, I
机构
[1] Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
关键词
D O I
10.1002/ana.410370615
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Inclusion body myositis developed in two men, 36 and 48 years old with long-standing common variable immunodeficiency. Immunophenotypic analysis of the endomysial cells showed an increased number of natural killer (NK) cells (defined as CD57(+), CD56(+), CD3(-), CD8(-), CD68(-)) accounting for 8.5 to 9.5% of the total cells, compared with a mean of 1% in sporadic inclusion body myositis. The remaining cells were CD8(+) macrophages, and CD4(+) T cells. NK cells were positive for intercellular cell adhesion molecule-1 and invaded muscle fibers negative for major histocompatibility complex (MHC) class 1. In contrast to ubiquitous endomysial expression of MHC class I antigen in sporadic inclusion body myositis, the MHC class I in common variable immunodeficiency and inclusion body myositis was absent or weakly expressed in only some of the muscle fibers surrounded by CD8(+) cells. Enteroviral or retroviral RNA sequences were not amplified. Treatment with intravenous immunoglobulin improved strength in 1 patient whose repeated muscle biopsy specimen showed normal NK cells. We conclude that inclusion body myositis can develop in patients with common variable immunodeficiency. Common variable Immunodeficiency with inclusion body myositis is an immune myopathy mediated by NK cells in a non-MHC class I-restricted cytotoxicity, and by CD8(+) cells in an MHC class I-restricted process. This is the first description of an inflammatory myopathy in which NK cells participate in the myocytotoxic process.
引用
收藏
页码:806 / 810
页数:5
相关论文
共 16 条
  • [1] Dalakas M, Polymyositis C., Dermatomyositis, and inclusion body myositis, N Engl J Med, 325, pp. 1487-1498, (1991)
  • [2] Sekul EA, Dalakas MC, Inclusion body myositis: new concepts, Semin Neurol, 13, pp. 256-263, (1993)
  • [3] Mikol J., Engel AG, Inclusion body myositis, Myology: basic and clinical, pp. 1384-1398, (1994)
  • [4] Engel AG, Arahata K., Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis, Ann Neurol, 16, pp. 209-215, (1984)
  • [5] Sneller MC, Strober W., Eisenstein E., Et al., New insights into common variable immunodeficiency, Ann Intern Med, 118, pp. 720-730, (1993)
  • [6] Leon-Monzon M., Illa I., Dalakas MC, Polymyositis in patients infected with human T‐cell leukemia virus type 1: the role of the virus in the cause of the disease, Annals of Neurology, 36, pp. 643-649, (1994)
  • [7] Illa I., Nath A., Dalakas MC, Immunocytochemical and virological characteristics of HIV‐associated inflammatory myopathies: similarities with seronegative polymyositis, Ann Neurol, 29, pp. 474-481, (1991)
  • [8] Illa I., Leon-Monzon M., Dalakas MC, Regenerating and denervated human muscle fibers and satellite cells express N‐CAM recognized by monoclonal antibodies to NK cells, Ann Neurol, 31, pp. 46-52, (1992)
  • [9] Dalakas MC, Illa I., Dambrosia J., Et al., A controlled trial of high‐dose intravenous immunoglobulin infusions as treatment for dermatomyositis, N Engl J Med, 329, pp. 1993-2000, (1993)
  • [10] Soueidan SA, Dalakas MC, Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin, Neurology, 43, pp. 876-879, (1993)